Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool September 30, 2011 Brian Orelli	We Don't Care if It's the First Lupus Drug in 50 Years The U.K.'s National Institute for Health and Clinical Excellence declines Glaxo and HGS' Benlysta.
The Motley Fool July 20, 2009 Brian Orelli	Overnight Triple! Yee-Haw! The joys of owning biotech companies. The latest beneficiary, Human Genome Sciences, is up more than 220% today because Benlysta, their new drug for lupus, works.
Investment Advisor August 2006	S&P Mutual Fund Sector Focus: Health Care Funds Tired and Sluggish Big pharma names dominate most health care funds and these businesses are beset with problems. One of the best longer-term performers in this area, the $561-million Schwab Health Care Fund.
The Motley Fool August 11, 2011 Brian Orelli	Dendreon's a Broken IPO, Again $10 isn't really a magical number.
The Motley Fool February 28, 2011 David Williamson	Don't Miss These Health-Care ETFs Two ways ETFs can help your portfolio
The Motley Fool November 16, 2009 Amanda B. Kish	The Hottest Sector for 2010 It's hard to argue that the potential benefits to this sector won't be significant if health care reform does work its way through. The time to stock up on high-quality health-care names is now.
The Motley Fool January 14, 2010 Brian Orelli	JPMorgan Challenge: Do You "Heart" This Company? A look at Edwards Lifesciences and its heart valves.
Financial Planning August 1, 2009 Ilana Polyak	Critical Care As Congress wrestles with healthcare reform proposals under consideration, Kris Jenner, manager of the T. Rowe Price Health Sciences fund, is faced with just as difficult a task: how to make prudent investments in healthcare that can weather the seismic changes in the offing.
Financial Planning February 1, 2007 Elizabeth O'Brien	Do No Harm Kris Jenner, manager of T. Rowe Price's Health Sciences Fund, has kept his fund healthy through changing economic climates.
The Motley Fool May 12, 2010 Matt Koppenheffer	Are Health-Care Stocks a Buy? Health-care stocks have underperformed the market so far this year. Is it time for a turnaround?
The Motley Fool July 25, 2006 Ryan Fuhrmann	A Steady Heartbeat at Edwards Can Edwards Lifesciences grow enough to justify its stock price?
The Motley Fool January 23, 2009 Brian Orelli	Wyeth Isn't Cheap Enough for Pfizer The Wall Street Journal reports that Pfizer is in talks to acquire Wyeth for $60 billion or more. Should they do it?
The Motley Fool December 9, 2008 Brian Orelli	Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences.
The Motley Fool November 16, 2006 Jim Fink	The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007.
The Motley Fool October 30, 2009 Brian Orelli	Earnings? Yawn. Trial Data? Moving! For Human Genome Sciences investors, the anticipation is frightening.
The Motley Fool June 30, 2010 Brian Orelli	Which Midsized Biotech Is the Best Buy? Biogen Idec, Amgen, or Gilead? Which of these biotechs has the most potential for growth?
The Motley Fool October 5, 2010 Brian Orelli	You Should Have Seen this FDA Rejection Coming This hepatitis C treatment was marked for failure.
The Motley Fool February 27, 2009 Brian Orelli	Waiting to Inhale Human Genome Sciences is guiding for revenue of $250 million this year compared to less than $50 million last year, thanks to its sale of anthrax emergency treatment ABthrax to the government.
BusinessWeek January 29, 2007 Arlene Weintraub	More Merger Mania Ahead For Pharma The scramble for new drugs is keeping companies on the prowl.
The Motley Fool August 23, 2005 W.D. Crotty	A Myriad of Revenue Myriad Genetics reports a solid fourth-quarter and fiscal year. Is this high-risk biotech concern worth a look?
The Motley Fool March 17, 2011 Brian Orelli	Eat or Be Eaten? Perhaps Both. Oft-rumored takeout target Human Genome Sciences goes shopping.
The Motley Fool January 14, 2010 Jim Mueller	Roundtable: Which Health-Care Stocks to Buy Now Three Fool analysts give you their best ideas on where to put your money after the health-care reform bill makes it out of Congress.
The Motley Fool May 20, 2011 Selena Maranjian	Beware These "Very Attractive" ETFs There are some big red flags here.
BusinessWeek March 22, 2004 Arlene Weintraub	Amgen Opens The Secret Curtain The biotech leader will host analysts and investors to drum up excitement for its pipeline -- and its stock. Will it work?
The Motley Fool September 30, 2011 David Williamson	This Week in Biotech Biotech news about Array BioPharma, Human Genome Sciences, Pharmasset, and more.
The Motley Fool May 22, 2009 Brian Orelli	J&J and Cougar: Meow or Roar? Health-care giant Johnson & Johnson is doing something that many of its investors -- Buffett included -- wouldn't do; it's buying a development-stage drugmaker that has no proven drugs.
The Motley Fool November 25, 2009 Brian Orelli	Novartis Didn't Know JAK, Until Now Incyte has something to be thankful for this week. Novartis is giving the company a wad of cash to license its most promising drug candidate for myelofibrosis
The Motley Fool April 14, 2011 Brian Orelli	Human Genome Sciences Will Be Profitable, Eventually With its first drug on the market -- nearly 20 years after the company was founded -- Human Genome Sciences should start to show meaningful revenue this year.
The Motley Fool November 2, 2009 Brian Orelli	Finally Convinced? Benlysta Works! Human Genome Sciences succeeds where others have failed.
The Motley Fool March 27, 2009 Brian Orelli	Trading Up With the $95 From Genentech Genentech is gone; here's what you should replace it with.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool December 22, 2009 Brian Orelli	Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon.
The Motley Fool May 27, 2009 Brian Orelli	A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452.
The Motley Fool January 11, 2010 Brian Orelli	Celgene Revs Up for a New Year Preliminary 2009 sales released at the J.P. Morgan Health Care Conference have sales up about 20% year over year and Celgene is guiding for 20% revenue growth next year as well.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
The Motley Fool October 26, 2011 Brian Orelli	Down 20%: Benylsta Not Ramping Fast Enough Sales of Human Genome Sciences' new lupus drug Benylsta continues to grow -- just not fast enough to keep investors interest.
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool December 9, 2011 Paul Chi	3 Europe-Proof Stocks for Your Portfolio These health-care stocks are Europe-proof.
The Motley Fool August 18, 2010 Travers & Jayson	The Most Important Thing About Human Genome Sciences Is Human Genome Sciences on strong financial footing? Take a look.
The Motley Fool March 13, 2006 Rick Aristotle Munarriz	Where Will You Be Tomorrow? Your stocks are set for the future. Now it's your turn.
The Motley Fool November 17, 2010 Brian Orelli	52 Years Down, 1 Month to Go Lupus treatment Benlysta moves closer to approval.
The Motley Fool March 31, 2011 Brian Orelli	Gilead's Long-Term Cancer Fight An academic partnership is a good sign it's serious.
The Motley Fool December 20, 2011 Luke Timmerman	Amgen, Watson Strike $400M Deal for Biosimilar Cancer Drugs What does this important collaboration mean for biosimilars?
The Motley Fool April 4, 2009 Brian Orelli	The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry.
The Motley Fool August 12, 2011 Selena Maranjian	Make Money in Health-Care Companies the Easy Way There's no need to guess which health-care company will perform best. A well-chosen ETF can grant you instant diversification across the industry -- and make investing in and profiting from its companies that much easier.
The Motley Fool July 22, 2011 Brian Orelli	It's How You Finish That Matters Human Genome Sciences gained approval of the first drug developed for lupus in half a century, but in its first full quarter on the market Benlysta was uninspiring.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.
The Motley Fool January 19, 2012 Sean Williams	No Vacancy: Workers Need Not Apply to This Sector Pharmaceutical and biotech layoffs are kicking into high gear.
The Motley Fool June 29, 2005 Karl Thiel	Cash In on the Future of Science With some diligence, you can ride your high school biology to biotech investing success.
Bio-IT World August 2005 G. Steven Burrill	Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market.